ccp-ab-to-cyclic-citrullinated-peptide CDK5 peptides are synthetic or derived molecules designed to interact with or mimic components of the Cyclin-Dependent Kinase 5 (CDK5) pathway. These peptides are primarily explored for their potential therapeutic applications, particularly in neurological disorders. Research indicates that CDK5 plays a crucial role in the central nervous system, and its aberrant activation is implicated in neurodegenerative conditions such as Alzheimer's disease and Parkinson's diseaseCDK5 Substrate [PKTPKKAKKL]. Consequently, the development of CDK5 peptide inhibitors or modulators has become a significant area of investigation.
Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that is essential for normal brain development and functionIdentification and Structure Characterization of a Cdk .... It is activated by its specific activators, p35 and p39. However, pathological cleavage of p35 generates a truncated form called p25. The accumulation of p25 leads to the formation of a hyperactive CDK5/p25 complex, which is strongly linked to neuronal death and neurodegeneration observed in various neurological diseases. This aberrant CDK5 activity can disrupt critical cellular processes, including synaptic function and neuronal survival.
The research surrounding CDK5 peptides focuses on several key strategies:
* CDK5 Inhibitory Peptides (CIPs): These peptides are designed to directly inhibit the activity of the CDK5/p25 complex. For instance, the Cdk5 Inhibitory Peptide (CIP), a 12-amino acid peptide derived from the T-loop of CDK5, has shown promise. Another variant, TFP5 (also known as TP5), derived from the CDK5 activator p35, has demonstrated neuroprotective effects by inhibiting pathological CDK5 hyperactivity. These peptides aim to restore normal cellular function and prevent neuronal damage. Some studies have also identified other CDK5-derived peptides, such as a 12-amino acid peptide that binds to the CDK5/p25 complex and interferes with p25 binding, offering a different mechanism of inhibition.
* Peptides Targeting Specific Interactions: Some peptides are engineered to disrupt the interaction between CDK5 and its activators or substrates.The Peptide-Directed Lysosomal Degradation of CDK5 ... For example, peptides derived from the CDK5 activator p35, like TFP5, can rescue dopaminergic neurodegeneration in models of Parkinson's disease. Research has also explored peptides derived from histone H1 sequences that can dock in the active site of CDK5, serving as substrates or inhibitors.作者：PC Pao·2023·被引用次数：47—We report a 12-amino-acid-longpeptidefragment derived fromCdk5(Cdk5i) that is considerably smaller than existingpeptideinhibitors ofCdk5(P5 and CIP)
* Blocking Peptides for Research: Synthetic peptides are also utilized as research tools, particularly in conjunction with antibodies.Cdk5i peptide consists of 12 amino acids(ARAFGIPVRCYS) that is derived from an activation loop (T-loop) of Cdk5 known as the important site for interacting ... These "blocking peptides" often contain the epitope recognized by a specific anti-CDK5 antibody. By binding to the antibody, they prevent it from interacting with the target CDK5 protein, thereby confirming antibody specificity and aiding in research assays.A Cdk5 inhibitory peptide reduces tau hyperphosphorylation ...
The therapeutic potential of CDK5 peptides lies in their ability to modulate a key pathway implicated in numerous debilitating neurological conditions作者：A Bosutti·2013·被引用次数：24—Cyclin-dependent kinase-5 (Cdk5) is over-expressed in both neurons and microvessels in hypoxic regions of stroke tissue and has a significant pathological .... By targeting the aberrant CDK5/p25 complex, these peptides offer a promising avenue for developing treatments for diseases like Alzheimer's, Parkinson's, and stroke, where neurodegeneration is a central feature. For example, TFP5 has been shown to protect pancreatic beta cells from apoptosis and enhance insulin secretion, suggesting potential applications beyond neurological disorders.
However, challenges remain in translating these findings into effective clinical therapies. These include ensuring the stability and delivery of peptides to the brain, optimizing their efficacy, minimizing off-target effects, and understanding long-term safety profiles. The development of non-naturally occurring peptide sequences aims to improve stability and binding affinity, but further research is needed to overcome these hurdles作者：SY Liu·2023·被引用次数：2—TFP5 effectively inhibited the pathological hyperactivity of Cdk5, enhanced insulin secretion, and protected pancreatic β cells from apoptosis in vitro and in ....
In conclusion, CDK5 peptide research represents a dynamic and critical area in the quest for novel therapeutics for neurodegenerative diseases.作者：PC Pao·2023·被引用次数：47—Here, we report a 12-amino acid longCdk5-derivedpeptidethat interferes with theCdk5/p25 complex and ameliorates neurodegenerative phenotypes in cell and ... By precisely targeting the complex regulatory mechanisms of CDK5, these peptides offer hope for interventions that can protect neuronal health and restore cognitive function.
Join the newsletter to receive news, updates, new products and freebies in your inbox.